Travere Therapeutics

Retrophin - Discovery and development of drugs to treat catastrophic diseases.

Launch date

2008

Employees

Market cap

Enterprise valuation

AUD1.6b (Public information from Sep 2024)

San Diego California (HQ)

http://retrophin.com

https://twitter.com/retrophin https://www.facebook.com/1558803391034818 https://www.linkedin.com/company/travererare/

Revenues, earnings & profits over time

EUR	2020	2021	2022	2023	2024	2025	2026
Revenues	180m	207m	193m	132m	206m	305m	419m
% growth	13 %	15 %	(7 %)	(31 %)	56 %	48 %	37 %
EBITDA	(62.7m)	(125m)	(222m)	(286m)	(185m)	(49.2m)	(<1m)
% EBITDA margin	(35 %)	(60 %)	(115 %)	(217 %)	(90 %)	(16 %)	-
Profit	(154m)	(164m)	(253m)	(101m)	(262m)	(133m)	(16.0m)
% profit margin	(85 %)	(79 %)	(131 %)	(77 %)	(127 %)	(44 %)	(4 %)
EV / revenue	6.3x	8.3x	6.0x	3.4x	3.9x	2.4x	2.1x
EV / EBITDA	-18.1x	-13.8x	-5.2x	-1.5x	-4.3x	-14.9x	-1157.8x
R&D budget	120m	191m	214m	223m	-	-	-
R&D % of revenue	66 %	92 %	111 %	169 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
-	Perceptive Advisors	N/A	-
Aug 2003	N/A	N/A	IPO
Jan 2012	N/A	N/A	Seed
Aug 2013	N/A	$25.0m	Post IPO Equity
May 2014	Athyrium Capital Management	$46.0m	Post IPO Equity
Jul 2014	Athyrium Capital Management	$45.0m	Post IPO Debt
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

Manchester Pharmaceuticals

ACQUISITION by Travere Therapeutics Feb 2014

Orphan Technologies

ACQUISITION by Travere Therapeutics Oct 2020